Clinical Trials Logo

Limb Girdle Muscular Dystrophy clinical trials

View clinical trials related to Limb Girdle Muscular Dystrophy.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05906251 Active, not recruiting - Clinical trials for Limb Girdle Muscular Dystrophy

A Gene Transfer Study to Evaluate the Safety, Tolerability and Efficacy of SRP-6004 in Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2B/R2 (LGMD2B/R2, Dysferlin [DYSF] Related)

Start date: May 22, 2023
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of SRP-6004 administered by intravenous (IV) infusion in ambulatory participants with LGMD2B/R2 (DYSF related).

NCT ID: NCT05876780 Active, not recruiting - Clinical trials for Limb Girdle Muscular Dystrophy

A Gene Transfer Single Dose Study to Evaluate the Safety, Tolerability and Efficacy of SRP-9003 in Non-Ambulatory and Ambulatory Participants With Limb Girdle Muscular Dystrophy, Type 2E/R4 (Beta-Sarcoglycan [β-SG] Deficiency)

Start date: December 19, 2022
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the safety of SRP-9003 and to quantify expression of β-SG in the skeletal muscle of participants with limb-girdle muscular dystrophy, type 2E/R4 (LGMD2E/R4). The study will include both ambulatory (Cohort 1) and non-ambulatory (Cohort 2) participants.

NCT ID: NCT05206617 Active, not recruiting - Clinical trials for Neuromuscular Diseases

3 Year Follow up on ANO5 Patients

Start date: January 1, 2018
Phase:
Study type: Observational

The aim of the study is to investigate progression in muscle affection in patients with pathogenic variants in the anoctamin 5 gene to: 1. investigate possible progression of disease over time 2. investigate good and reliable outcome measures

NCT ID: NCT03930628 Active, not recruiting - Clinical trials for Muscular Dystrophies

Limb-Girdle Muscular Dystrophy Type 2I in Norway

Start date: January 6, 2020
Phase:
Study type: Observational

Key goals are to establish the natural history of limb-girdle muscular dystrophy type 2I (LGMD 2I) and identify feasible and sensitive tools and biomarkers to measure disease affection and progression, determine the Norwegian LGMD 2I prevalence, carrier frequency and genotypes, and to assess health-related quality of life in the Norwegian LGMD 2I population. Main aims are to facilitate future clinical trials and contribute to good clinical practice with suitable methodology and to complete health and social care in order to optimize the function and quality of daily living of the patient group.